Literature DB >> 22865544

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Cécile Goujard1, Isabelle Girault, Christine Rouzioux, Camille Lécuroux, Christiane Deveau, Marie-Laure Chaix, Christine Jacomet, Amel Talamali, Jean-François Delfraissy, Alain Venet, Laurence Meyer, Martine Sinet.   

Abstract

BACKGROUND: The occurrence of viral control after interruption of an antiretroviral treatment (ART) initiated during primary HIV-1 infection (PHI) is rare and the frequency and predictive factors of such a control are unknown.
METHODS: Within the French ANRS PRIMO Cohort, 164 patients interrupted ART initiated during PHI. We compared patients whose viral load (VL) remained undetectable (<50 copies/ml) or low (50-500 copies/ml) 1 year after ART interruption to those who evidenced a rapid viral rebound.
RESULTS: After ART interruption, VL remained undetectable for a median time of 4.5 years in 14 patients ('post-ART controllers') and low in another 14 patients for a median time of 1.5 years. Post-ART controllers also maintained higher CD4(+) T-cell counts compared to other patients. Female gender, a high CD4(+) T-cell count and low VL during PHI, and a high CD4(+) T-cell count and low HIV DNA levels at interruption, were associated with post-ART HIV control. Treatment characteristics did not differ between controllers and non-controllers. Post-ART controllers had lower specific CD8(+) T-cell frequencies and CD8(+) T-cell activation on ART and after ART interruption than non-controllers.
CONCLUSIONS: Few patients maintain very low VL after interruption of treatment initiated during PHI. Early patient characteristics were the main factors of viral control, although early initiation of ART and the effect of ART on reservoir might contribute to control.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865544     DOI: 10.3851/IMP2273

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  51 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.

Authors:  Zachary Strongin; Luca Micci; Rémi Fromentin; Justin Harper; Julia McBrien; Emily Ryan; Neeta Shenvi; Kirk Easley; Nicolas Chomont; Guido Silvestri; Mirko Paiardini
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

4.  HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Authors:  Radwa Sharaf; Guinevere Q Lee; Xiaoming Sun; Behzad Etemad; Layla M Aboukhater; Zixin Hu; Zabrina L Brumme; Evgenia Aga; Ronald J Bosch; Ying Wen; Golnaz Namazi; Ce Gao; Edward P Acosta; Rajesh T Gandhi; Jeffrey M Jacobson; Daniel Skiest; David M Margolis; Ronald Mitsuyasu; Paul Volberding; Elizabeth Connick; Daniel R Kuritzkes; Michael M Lederman; Xu G Yu; Mathias Lichterfeld; Jonathan Z Li
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

5.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

Review 6.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Authors:  Christine Katlama; Steven G Deeks; Brigitte Autran; Javier Martinez-Picado; Jan van Lunzen; Christine Rouzioux; Michael Miller; Stefano Vella; Joern E Schmitz; Jeffrey Ahlers; Douglas D Richman; Rafick P Sekaly
Journal:  Lancet       Date:  2013-03-29       Impact factor: 79.321

7.  Wake me up before you go: a strategy to reduce the latent HIV reservoir.

Authors:  Nicolas Chomont; Afam A Okoye; David Favre; Lydie Trautmann
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

8.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

Review 9.  Mathematical Models of HIV Latency.

Authors:  Alison L Hill
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

10.  Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Authors:  Nicolas Noel; Ruth Peña; Annie David; Veronique Avettand-Fenoel; Itziar Erkizia; Esther Jimenez; Camille Lecuroux; Christine Rouzioux; Faroudy Boufassa; Gianfranco Pancino; Alain Venet; Carine Van Lint; Javier Martinez-Picado; Olivier Lambotte; Asier Sáez-Cirión; Julia G Prado
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.